



**BETTER SLEEP, BETTER HEALTH**  
*and a BETTER LIFE*

21 December 2017

**ASX RELEASE**

**Cleansing Notice – Placement**

Oventus Medical Limited (ASX: OVN) (**Oventus**) has issued an additional 13,799,947 fully paid ordinary shares to sophisticated investors by way of a placement, at an issue price of \$0.55 per share as outlined in Oventus' announcement of 13 December 2017.

Oventus has issued the shares without disclosure to investors under section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**).

**Details of the securities issued**

<b>Class of securities:</b>	Ordinary shares
<b>ASX Code of the securities:</b>	OVN
<b>Date of the issue of the securities:</b>	Thursday 21 December 2017
<b>Total number of securities issued or expected to be issued:</b>	13,799,947

As required by section 708A(6) of the Corporations Act, Oventus advises:

- (a) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Oventus has complied with:
  - (i) the provisions of chapter 2M of the Corporations Act as they apply to Oventus; and
  - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act).

An Appendix 3B reflecting the revised capital structure following the issue of the shares under the placement has been separately announced.

For and on behalf of the board of Oventus.

Mel Bridges  
Chairman  
Oventus Medical Limited

-ENDS-

For more information please contact:

Dr Mel Bridges, Chairman: M: 0413 051 600 (+61 41 3051 600)

Visit our website <http://oventus.com.au>

#### **About Oventus**

Oventus is a Brisbane, Australia, based medical device company that has commercialized and brought to market a new **sleep treatment platform** for the treatment of sleep apnoea and snoring that enhances the treatment outcomes of both oral appliance therapy and CPAP therapy through increased efficacy and greater adherence.

**Oral appliance:** Oventus' unique and patented 'Airway Technology' incorporated into an oral appliance, the O<sub>2</sub>Vent™, bypasses multiple levels of breathing obstruction including the nose, soft palate and tongue.

Our appliances are particularly designed for sufferers with nasal obstructions, soft palate collapse and who consequently tend to breathe through their mouth while sleeping.

In action, when nasal obstruction is present, breathing is supplemented through the O<sub>2</sub>Vent™'s integrated 'Airways' delivering air to the back of the mouth while maintaining an oral seal, stabilizing the tongue base, bypassing obstructions in the nose and soft palate and reducing the collapsibility of the upper airway. However, when the nose is unobstructed, the O<sub>2</sub>Vent™ allows for natural nasal breathing.

**'O<sub>2</sub>Vent™ Connect' Positive Airway Pressure (PAP) Connection:** Severe sleep apnoea sufferers who have traditionally used a CPAP machine and full facemask can use Oventus' O<sub>2</sub>Vent™ oral appliance to interface with CPAP reducing operating pressure by around 66%, eliminating the need for straps and allowing physiologic mouth breathing while delivering CPAP. This has allowed for a re-design of the CPAP delivery system which is far less intrusive (without full face mask and straps), called the 'O<sub>2</sub>Vent™ Connect'.

Oventus' O<sub>2</sub>Vent™ Connect' attaches to the front of the O<sub>2</sub>Vent™, thereby doing away with the full face mask, while bringing air from the CPAP machine to the nasal opening at lower pressure.

**Clinical trials:** Over 50 patients to date have shown Oventus' O<sub>2</sub>Vent™ is successful in treating Obstructive Sleep Apnoea (OSA) by an additional 30-50% and that snoring was either eliminated or significantly reduced, when compared to mandibular or "jaw" advancement oral appliances which primarily reduce tongue based breathing obstruction. The positive results included those sufferers who had nasal obstructions and mainly breath through the mouth.

**Market:** According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.<sup>1</sup>

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP<sup>2</sup> due to discomfort caused from high operating pressure and low tolerance for a full face mask.

**The Oventus oral appliance 'Airway Technology' in the O<sub>2</sub>Vent™ when incorporated with Oventus' 'O<sub>2</sub>Vent™ Connect' allows sufferers to breathe physiologically through the mouth or through the nose whilst simultaneously delivering CPAP. Mild sufferers are able to solely wear the O<sub>2</sub>Vent™ oral appliance.**

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

<sup>1</sup> Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010*. Canberra, Australia.

<sup>2</sup> Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. *Chest* 124:2200-2208, 2003.